Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oxford University

- PMLiVE

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

UK flag

Universal flu vaccine heads for UK trials

New vaccine targets core proteins of the virus

- PMLiVE

Mitsubishi buys Israel’s NeuroDerm for $1.1bn

The deal will see it focus on a series of drug-device combinations for Parkinson’s disease, headed by phase III candidate ND0612

- PMLiVE

Microsoft creates ‘Emma’ to aid with Parkinson’s

Prototype watch reduces uncontrollable shaking

- PMLiVE

UCB adds website for its Facebook-based Parkinson’s community

Says the site forms the next chapter for More than Motion

- PMLiVE

FDA approves Newron’s Parkinson’s disease drug Xadago

Becomes first new treatment licensed for the condition in over a decade

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

- PMLiVE

Yoshinori Ohsumi wins Nobel Prize in Medicine for autophagy work

Receives the accolade for his discoveries of mechanisms for the cell process

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links